Paper Details

  1. Home
  2. Paper Details

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Author: BryantJ, CleggA J, CooperK, PicotJ

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Multiple myeloma (MM) is a common type of blood cancer. While it is not curable, treatment with supportive care and chemotherapy aims to extend life and improve quality of life. Most patients can't tolerate intensive treatment like high-dose chemotherapy with stem cell transplants, so they receive single or combination chemotherapy. Common combinations include an alkylating agent and a corticosteroid. More recently, drugs like thalidomide and bortezomib have been added to these combinations.
Paper Details　
Original Abstract of the Article :
Multiple myeloma (MM) is the second most common haematological cancer in the UK. MM is not curable but can be treated with a combination of supportive measures and chemotherapy that aim to extend the duration and quality of survival. The majority of patients are not able to withstand intensive treat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781217/

データ提供：米国国立医学図書館（NLM）

The Effectiveness and Cost-Effectiveness of Bortezomib and Thalidomide in Treating Multiple Myeloma

This research delves into the world of hematological cancers, specifically multiple myeloma (MM), which is the second most common type in the UK. Like a stubborn camel refusing to leave a lush oasis, MM can be difficult to eradicate. While a combination of supportive measures and chemotherapy can extend survival, the majority of patients can't handle intensive treatments. This study aims to evaluate the effectiveness and cost-effectiveness of bortezomib and thalidomide, two new players in the chemotherapy game, when combined with traditional alkylating agents and corticosteroids. The authors found that these combination therapies offer promising results, potentially leading to a more tolerable and effective treatment plan for patients with MM.

A New Frontier for Multiple Myeloma Treatment

This research highlights the potential of bortezomib and thalidomide in combination therapies for MM. The study suggests these new combinations may be a more effective and tolerable option for patients who cannot withstand intensive treatments. The findings can be particularly helpful for doctors in choosing the best treatment strategy for individual patients.

Moving Towards Personalized Treatment for Multiple Myeloma

The study encourages the development of personalized treatment plans for MM, taking into account individual patient needs and tolerance levels. It emphasizes that these new combination therapies may provide a safer and more effective approach to managing this challenging disease, potentially leading to a better quality of life for patients.

Dr. Camel's Conclusion

This research shines a light on the promise of personalized treatment for MM. It's like finding a hidden spring in the desert - a source of hope and potential for a better future. The study's findings will help doctors tailor treatment to individual patients, ensuring that they receive the most effective and tolerable care.

Date :
  1. Date Completed 2012-04-09
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22146234

DOI: Digital Object Identifier

PMC4781217

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.